

# Professional Provider Report

A newsletter for professional providers and their staff members

March 2024 - S-1-24

## What's Inside

Reminders Regarding Utilization of Spinal Imaging .....	1
Federal Employee Program (FEP) Colorectal Screening Pilot .....	2
IV Loading SQ Maintenance .....	2
2024 BCBSKS Workshops Now Available. Sign up Today! .....	3
Format Change to Medical RX Policies .....	4
2024 Blue Medicare Advantage Stars Incentive Program .....	4
Provider Support: Change Healthcare Cyber Security Issue .....	5
Risk Adjustment .....	5
QBRP Prerequisite Reminder .....	6
Reminder: The CAA Requires Provider Directory Information to be Validated at Least Every 90 days.....	6
Web Changes - Medical Policy .....	6

## Reminders Regarding Utilization of Spinal Imaging

Avoid routine spinal imaging in the absence of clear clinical indicators for patients with acute pain of less than six (6) weeks duration. Such indicators include, but are not limited to:

- Signs or symptoms of cauda equina syndrome
- Significant neurologic deficits
- Current/recent and/or high risk for cancer (other than nonmelanoma skin cancer)
- Signs, symptoms, and risk factors for spinal infection
- Risk and/or suspected compression fractures based off of history and/or trauma
- A shock-like paresthesia occurring with neck flexion

Must also consider conditions that potentially preclude a dynamic thrust to the spine, which include but are not limited to osteopenia, osteoporosis, axial spondylarthritis, and tumors.

Do not perform repeat imaging to monitor patients' progress. Providers must bill diagnostic x-ray services utilizing CPT radiology codes and adhere to the policies and procedures described in Policy Memo No. 7 Radiology and Pathology.

The Professional Provider Report is published by the Professional Relations department of Blue Cross and Blue Shield of Kansas.

Sarah Shaw,  
Communications Coordinator



BlueCross BlueShield

**Kansas**

[bcbsks.com](http://bcbsks.com)



## Federal Employee Program (FEP) Colorectal Screening Pilot

Blue Cross Blue Shield of Kansas (BCBSKS) is committed to providing its members with the best preventive care options. In 2024, BCBSKS will start a pilot program that will focus on closing Colorectal Screening gaps in care for their Federal Employee Program members between the ages of 45-75. Members will be offered a monetary gift card for participating in an approved colorectal screening test between the months of May and November. Members will receive their reward once claims are received by BCBSKS. These gaps in care can be addressed by any of the following tests: fecal occult blood test, DNA analysis of stool samples, colonoscopy with or without biopsy, sigmoidoscopy, double contrast barium enema or CT colonography.

A wellness mailer, reminding members of the importance of screening, will begin to be sent to qualified members in April 2024. The mailer will encourage them to contact their provider for screening. They will be encouraged to discuss the most appropriate form of screening for their individual needs. For your reference, the adult preventive Colorectal Cancer Screening benefit includes coverage for the above-mentioned forms of testing. Preventive care benefits are provided for one of each type of Colorectal Cancer Screening per calendar year on professional and outpatient facility claims, regardless of diagnosis code. Any subsequent test would then be subject to member cost share. Our hope is that by working together we can provide more preventive care to our members.

## IV loading SQ maintenance

At Blue Cross and Blue Shield of Kansas (BCBSKS), we consistently look for ways to improve member and provider experiences without compromising quality. We have identified an opportunity to improve a process that will reduce provider workload burden and reduce potential member confusion. Certain medications used for the treatment of Crohn's Disease and Ulcerative Colitis require an intravenous (IV) induction dose, and then subcutaneous (SQ) maintenance dosing. Examples include Stelara, Skyrizi, and Omvoh. Some providers have expressed confusion over where to send the Prior Authorization (PA) requests for these products. As a result, we have streamlined our PA processes for these products to improve the process. Effective immediately, for members who have medical benefits with BCBSKS and pharmacy benefits with Prime Therapeutics, please follow the following steps:

- Send the SQ maintenance PA request to Prime Therapeutics
- If the PA for maintenance dosing is approved by Prime Therapeutics, BCBSKS has implemented processes to authorize claims for FDA-approved IV loading dose(s) without the need to submit a PA for the IV dose(s).
- You may administer FDA-approved IV loading dose(s) once you have received the SQ approval for these products
- No IV loading dose request will be required to be sent to BCBSKS or to Prime. If an IV PA is sent to Prime, it may be sent back with instructions that Prime does not review the IV request.

The above process only applies to members who have BCBSKS medical benefits and who have pharmacy benefits which are reviewed by Prime Therapeutics. If you have any additional questions about this new process, reach out to your BCBSKS provider representative.



## 2024 BCBSKS workshops now available. Sign up today!

Blue Cross and Blue Shield of Kansas (BCBSKS) would like providers to know they can now sign up for our Behavioral Health, Insurance Biller's, Dental, and What's New in 2025 workshops.

Below are listed the dates currently scheduled for workshops in 2024. Please note, all workshops will be at 9am - 12:30pm unless otherwise indicated and held virtually through Teams:

### Behavioral Health workshops:

- New Biller Behavioral Health workshop - Thursday, **March 7th**. from **9am - 11am**. Pre-registration is required. [Click here to complete the registration process.](#)
- Treatment of Depression in Pregnant and Post-Partum Women's Behavioral Health workshop - Monday, **September 16th**. from **9am - 11:30am**. Pre-registration is required. [Click here to complete the registration process.](#)

### Insurance Biller's workshops:

- Thursday, **April 11th**. Pre-registration is required. [Click here to complete the registration process.](#)
- Tuesday, **May 7th**. Pre-registration is required. [Click here to complete the registration process.](#)

- Wednesday, **June 12th**. [Pre-registration is required. Click here to complete the registration process.](#)

### Dental workshops:

- Friday, **August 9th**. from **9am - 11am**. Pre-registration is required. [Click here to complete the registration process.](#)
- Tuesday, **August 20th**. from **1pm - 3pm**. Pre-registration is required. [Click here to complete the registration process.](#)

### What's New in 2025 workshops:

- Thursday, **September 26th**. Pre-registration is required. [Click here to complete the registration process.](#)
- Wednesday, **October 9th**. Pre-registration is required. [Click here to complete the registration process.](#)
- Tuesday, **November 12th**. Pre-registration is required. [Click here to complete the registration process.](#)

This is not an all-inclusive list, dates are subject to change, be cancelled, or additional dates added at any time, including our Annual Workshop. For more information regarding BCBSKS workshops, please visit, <https://www.bcbsks.com/providers/professional/education>.

If you have any questions regarding this publication, please contact your BCBSKS provider representative.

## Format change to medical Rx policies

In 2023, Blue Cross and Blue Shield of Kansas's (BCBSKS) pharmacy benefit manager (PBM) Prime Therapeutics acquired, medical drug management company, Magellan Rx Management. Prime Therapeutics previously assisted BCBSKS in medical Rx policy development, but Magellan Rx Management will now also provide medical Rx policies to BCBSKS.

As a result, you will see some policies posted to our website that have the new Magellan Rx Management format. Policies posted under the standard Prime Therapeutics format you are accustomed to will not go away. While the Magellan Rx Management policies will look different, the process for submitting requests, and the review process, will not be any different.

Please feel free to contact your provider representative if you have any questions.

## 2024 Blue Medicare Advantage Stars Incentive Program

Recently, Blue Cross and Blue Shield of Kansas (BCBSKS) announced the 2024 Blue Medicare Advantage (MA) Stars Incentive Program. This program rewards MA contracting primary care providers for the quality care they deliver to our fellow Kansans. Please visit our [2024 Understanding STAR Ratings guide](#) for specific details regarding the 2024 measures and incentives.

### Important dates to remember::

- [June 2024](#) - Final 2023 MA Stars Incentive Program Scorecards and payout
- [April 2024 through January 2025](#) - Monthly Scorecards and Member-level Detail Reports for 2024 measurement year delivered by email

- [December 16, 2024](#) - Deadline to submit supplemental data for gap closure
- [February 28, 2025](#) - Deadline to submit claims for gap closure
- [Q2 2025](#) - Payout for 2024 MA Stars Incentive Program

### Questions?

If you have questions regarding this publication, please contact your MA Professional Relations Representative or Institutional Relations Government Programs Provider Representative, or visit the [MA Provider section of our website](#).





# Provider Support: Change Healthcare Cyber Security Issue

Blue Cross and Blue Shield of Kansas (BCBSKS) Cyber Security Team has been made aware that Change Healthcare (CHC) is experiencing a network interruption related to a cyber security issue and their security experts are working to address the matter. It was communicated that CHC will provide updates as more information becomes available.

As a result of the cyber security situation still occurring with CHC, to protect our customers, BCBSKS has disabled trading partner accounts that we have related to CHC. As a result, there are a number of providers that are unable to submit claims or receive electronic remittance advices from BCBSKS.

BCBSKS wanted to reach out to make providers aware and offer potential other options for providers to continue to submit claims electronically:

- If providers have other means to partner with another vendor/trading partner, they can do that.
- If providers have the ability to submit an 837 and receive 835s from us, they can connect to BCBSKS directly if they submit a new trading partner enrollment form for this purpose.
- Another option only applicable to the submission claims might be to use our free billing software (PCAce) that is a more manual process, but it would accomplish the same result.

If the other options provided to continue to submit electronic claims are not viable, providers may drop their claims to paper and submit to BCBSKS. Providers can reach out directly to our ASKEDI Help Desk via email or phone.

- Email - [askedi@ask-edi.com](mailto:askedi@ask-edi.com)
- Phone – 785-291-4178 or 1-800-472-6481

CHC is providing regular status updates at, Optum Solutions Status - Update: Some applications are experiencing connectivity issues. ([changehealthcare.com](http://changehealthcare.com)).

## Risk Adjustment

Risk adjustment is a CMS model that estimates the healthcare costs of insuring Medicare Advantage and Affordable Care Act members based on their associated risk. A risk adjustment factor (RAF) is calculated for each member based on age, sex, health conditions and socioeconomic status. Here at Blue Cross and Blue Shield of Kansas, we want to make sure our Medicare Advantage members health conditions are captured as accurately as possible to ensure members are receiving the quality care they need. To help with that we may send providers member specific forms with suspected conditions called CDI Alerts (Clinical Documentation Improvement)/PAF forms (Patient Assessment Forms). Remember to return the PAF/CDI and include ICD-10s in the claim!

Best Practices for Risk Adjustment documentation:

- Make sure that the patient's name and date of birth is documented on each page of the medical record.
- Use clear and definitive language (avoid acronyms) to detail documentation to the highest level of specificity.
- Include updates on assessment and treatment for each diagnosis (i.e., "assessment: improving," "treatment plan: continue medication," etc.).
- Ask about conditions reflected in past visit notes to reaffirm prior chronic condition.
- Confirm that the physician signature, credentials and date are all included to authenticate the medical record.
- Make sure claims are tied to an encounter. The more information, the more accurate and comprehensive the medical record. Just remember: When in doubt, document!
- Verify that any list of medication explicitly ties to treatment plans.
- Use explicit verbiage to link related conditions (i.e., "due to", "with", "diabetic," etc.)

The above process only applies to members who have

BCBSKS medical benefits and who have pharmacy benefits which are reviewed by Prime Therapeutics. If you have any additional questions about this new process, reach out to your BCBSKS provider representative.

Include MEAT in your documentation. The acronym MEAT is used to describe the types of documentation in the medical record that would support the assignment and reporting of ICD-10CM diagnosis codes:

- M** Monitoring by ordering or referencing lab results, imaging studies, or other test.
- E** Evaluation with a targeted part of the physical examination specific to a certain diagnosis
- A** Assessment of the status, progression or severity of the diagnosis
- T** Treatment with medication, surgical intervention or lifestyle modification. Treatment also includes referral to a specialist for consultation or management.

## QBRP Prerequisite Reminder

Blue Cross and Blue Shield of Kansas (BCBSKS) would like to remind providers of the QBRP participation prerequisite that providers must conduct business with BCBSKS electronically, including receiving all communications (newsletters, etc.) electronically.

This requires that providers must maintain a valid email address signed up for our e-news. This includes entering an invalid email address, staffing changes and a new email address does not sign up for our e-news, etc.

Please note, if a valid email address is not signed up for our e-news, providers will lose all QBRP incentives. Please ensure your office has a valid email address signed up by May to ensure you do not lose your QBRP incentives.

You can sign up for our e-news on our website, <https://www.bcbsks.com/providers/professional/e-news>.

If you have additional questions, please contact your provider representative.

## Reminder: The CAA Requires Provider Directory Information to be Validated at Least Every 90 Days

Blue Cross and Blue Shield of Kansas (BCBSKS) would like to remind providers that the Consolidated Appropriations Act (CAA) outlines requirements for maintaining and validating information to include provider directories (CAA Section 116).

To comply with CAA provisions, BCBSKS must provide and regularly maintain our online provider directory to members. Providers must validate their information at least every 90 days through the provider portal to remain listed in the on-line National Doc Finder. This allows BCBSKS members/your patients to locate providers within the BCBSKS network.

Please note: If you miss validating your information, you will be suppressed from our provider directory.

## Web changes - Medical Policy

Since the publication of Professional Provider Report S-3-21, the following policies have been posted at: <https://www.bcbsks.com/CustomerService/Providers/MedicalPolicies/policies.shtml>

- Autologous Chondrocyte Implantation for Focal Articular Cartilage Lesions
- Cardiac Hemodynamic Monitoring for the Management of Heart Failure in the Outpatient Setting
- Homocysteine Testing
- ACA Prevention Copay Waiver Criteria – Individual Marketplace, Commercial
- Accelerated Breast Irradiation and Brachytherapy Boost After Breast-Conserving Surgery for Early-Stage Breast Cancer
- Adjustable Cranial Orthoses for Positional Plagiocephaly and Craniosynostoses
- Aducanumab (Aduhelm) for Alzheimer Disease
- Alcohol Injection Therapy for Morton's Neuroma
- Amniotic Membrane and Amniotic Fluid
- Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening
- Aqueous Shunts and Stents for Glaucoma
- Artificial Pancreas Device Systems

- Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer
- Balloon Dilatation of the Eustachian Tube
- Balloon Ostial Dilatation for Treatment of Chronic and Recurrent Acute Rhinosinusitis
- Bio-Engineered Skin and Soft Tissue Substitute
- Bioimpedance Devices for Detection and Management of Lymphedema
- Biologic Immunomodulators
- Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Breast Cancer
- Bone Mineral Density Studies
- Botulinum Toxin (BT)
- Breast Reconstructive Surgery After Mastectomy
- Bronchial Thermoplasty
- Cardiac Hemodynamic Monitoring for the Management of Heart Failure in the Outpatient Setting
- Cardiac Rehabilitation in the Outpatient Setting
- Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions
- Chelation Therapy for Off-Label Uses
- Cibinq
- Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)
- Cochlear Implant
- Comprehensive Genomic Profiling for Selecting Targeted Cancer Therapies
- Computed Tomography (CT) to Detect Coronary Artery Calcification
- Cone Beam Computed Tomography
- Continuous Glucose Monitoring
- Continuous Passive Motion in the Home Setting
- Contrast-Enhanced Coronary Computed Tomography Angiography (CCTA) for Coronary Artery Evaluation
- Corneal Collagen Cross-Linking
- Corneal Topography/Computer-Assisted Corneal Topography/Photokeratoscopy
- Coronary Computed Tomography Angiography with Selective Noninvasive Fractional Flow Reserve
- Cryoablation of Tumors Located in the Kidney, Lung, Breast, Pancreas, or Bone
- Cryosurgical Ablation of Primary or Metastatic Liver Tumors
- Cytochrome p450 Genotype- Guided Treatment Strategy
- Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
- Diagnosis and Medical Management of Obstructive Sleep Apnea Syndrome
- Diagnosis and Treatment of Sacroiliac Joint Pain
- Drug Testing in Pain Management and Substance Use Disorder Treatment
- Dry Needling of Myofascial Trigger Points
- Electrical Stimulation Devices for Home and Provider Use
- Electromyography and Nerve Conduction Studies
- Electronic Brachytherapy for Nonmelanoma Skin Cancer
- Elevidys® (delandistrogene moxeparvovec-rokl) (Intravenous)
- Endoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus
- Esketamine Nasal Spray for Depression
- Esophageal pH Monitoring
- Extracorporeal Shock Wave Therapy (ESWT) for Plantar Fasciitis and Other Musculoskeletal Conditions
- Facet Joint Denervation
- Fundus Photography
- Gastric Electrical Stimulation
- Gene Expression Profile Testing and Circulating Tumor DNA Testing for Predicting Recurrence in Colon Cancer
- Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management
- Gene Expression Profiling for Uveal Melanoma
- Gene Expression-Based Assays for Cancers of Unknown Primary
- General Approach to Evaluating the Utility of Genetic Panels
- General Approach to Genetic Testing
- Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
- Genetic Cancer Susceptibility Panels Using Next Generation Sequencing
- Genetic Testing for Cardiac Ion Channelopathies
- Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
- Genetic Testing for Marfan Syndrome, Thoracic Aortic Aneurysms and Dissections, and Related Disorders
- Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy
- Genetic Testing for the Diagnosis of Inherited Peripheral Neuropathies
- Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Breast Cancer
- Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Breast Cancer (BRCA1, BRCA2, PIK3CA, Ki-67, RET, BRAF, ESR1)
- Germline Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers
- Germline Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers (BRCA1, BRCA2, PALB2)
- Hemophilia B Gene Therapy Medical Drug Criteria Program Summary
- High-Sensitivity C-Reactive Protein
- Homocysteine Testing
- Human Growth Hormone
- Hydrogel Spacer use During Radiotherapy for Prostate Cancer
- Hyperbaric Oxygen Therapy (HBOT)
- Hyperthermic Intraperitoneal Chemotherapy for Select Intra-

- Abdominal and Pelvic Malignancies
- Identification of Microorganisms Using Nucleic Acid Testing
- IL-1 Inhibitors
- IL-4 Inhibitor
- IL-5 Inhibitors
- Immunoglobulin Therapy
- Implanted Peripheral Nerve Stimulator (PNS) for Pain Control
- Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
- Intensity Modulated Radiotherapy (IMRT)
- Intensity-Modulated Radiotherapy
- Interventions for Progressive Scoliosis
- Intra-Articular Hyaluronan Injections for Osteoarthritis
- Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric Disorders
- Intravenous Antibiotic Therapy and Associated Diagnostic Testing for Lyme Disease
- Intravenous Iron Replacement Therapy
- IV Iron
- Laboratory Tests Post Transplant and for Heart Failure
- Leadless Cardiac Pacemakers
- Low Intensity Pulsed Ultrasound Fracture Healing Device
- Low Level Laser Therapy
- Lumbar Spinal Fusion
- Lupus
- Magnetic Resonance Imaging (MRI) of the Breast
- Magnetic Resonance Spectroscopy
- Measurement of Exhaled Nitric Oxide and Exhaled Breath Condensate in the Diagnosis and Management of Respiratory Disorders
- Measurement of Lipoprotein-Associated Phospholipase A2 in the Assessment of Cardiovascular Risk
- Measurement of Serum Antibodies to Selected Biologic Agents
- Microprocessor-Controlled Prostheses for the Lower Limb
- Microwave Tumor Ablation
- Minimally Invasive Ablation Procedures for Morton and Other Peripheral Neuromas
- Molecular Markers in Fine Needle Aspiration of the Thyroid
- Molecular Testing for the Management of Pancreatic Cysts, Barrett's Esophagus, and Solid Pancreaticobiliary Lesions
- Monitored Anesthesia Care
- Multitarget Polymerase Chain Reaction Testing for Diagnosis of Bacterial Vaginosis
- Myoelectric Prosthetic Components for the Upper Limb
- Negative Pressure Wound Therapy in the Outpatient Setting
- Nerve Block Injections
- Non-invasive Positive Airway Pressure for Chronic Obstructive Pulmonary Disease (COPD)
- Noninvasive Prenatal Screening for Fetal Aneuploidies, Microdeletions, Single-Gene Disorders, and Twin Zygosity Using Cell-Free Fetal DNA
- Noninvasive Techniques for the Evaluation and Monitoring of Patients with Chronic Liver Disease
- Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
- Off-Label, Approved Orphan, and Expanded Access (Compassionate Use) Drugs
- Optical Coherence Tomography (OCT) of the Anterior Eye Segment
- Opzelura
- Orthopedic Applications of Platelet-Rich Plasma
- Orthopedic Applications of Stem Cell Therapy (Including Allograft and Bone Substitute Products Used With Autologous Bone Marrow)
- Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Disorders
- Outpatient Pulmonary Rehabilitation
- Pachymetry
- Panniculectomy and Abdominoplasty
- Patient-Controlled End Range of Motion Stretching Devices
- Percutaneous and Subcutaneous Tibial Nerve Stimulation
- Percutaneous Balloon Kyphoplasty, Radiofrequency Kyphoplasty, and Mechanical Vertebral Augmentation
- Percutaneous Electrical Nerve Stimulation and Percutaneous Neuromodulation Therapy, and Restorative Neurostimulation Therapy
- Percutaneous Intradiscal Electrothermal Annuloplasty, Radiofrequency Annuloplasty, Biacuplasty and Intraosseous Basivertebral Nerve Ablation
- Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
- Percutaneous Tibial Nerve Stimulation
- Percutaneous Vertebroplasty and Sacroplasty
- Periodontal Soft Tissue Grafting
- Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux (VUR)
- Photodynamic Therapy for Choroidal Neovascularization
- Plugs for Anal Fistula Repair
- Pneumatic Compression Pumps for Treatment of Lymphedema and Venous Ulcers (for Home Use)
- Pneumatic Compression Pumps for Treatment of Lymphedema and Venous Ulcers (for Home Use)
- Positron Emission Tomography (PET) Scanning: Cardiac Applications
- Positron Emission Tomography (PET) Scanning: In Oncology to Detect Early Response During Treatment
- Positron Emission Tomography (PET) Scanning: Miscellaneous (Non-cardiac, Non-Oncologic) Applications of Fluorine 18 Fluorodeoxyglucose
- Positron Emission Tomography (PET) Scanning: Oncologic Applications
- Postsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
- Prostatic Urethral Lift
- Proteomic Testing for Systemic Therapy in Non-Small-Cell Lung Cancer
- Radioembolization for Primary and Metastatic Tumors of the Liver



- Radiofrequency Ablation (RFA) of Miscellaneous Solid Tumors Excluding Liver Tumors
- Radiofrequency Ablation of Primary or Metastatic Liver Tumor
- Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions
- Reduction Mammoplasty for Breast-Related Symptoms
- Risk-Reducing Mastectomy
- Sacral Nerve Neuromodulation / Stimulation
- Scintimammography and Gamma Imaging of the Breast and Axilla
- Screening for Lung Cancer Using CT Scanning
- Serologic Diagnosis of Celiac Disease
- Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease
- Sex Reassignment Surgery
- Site of Care Infusion Management
- Skysona
- Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Non-Small-Cell Lung Cancer (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS, HER2, PD-L1, TMB)
- Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Metastatic Colorectal Cancer (KRAS, NRAS, BRAF, and HER2)
- Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Non-Small-Cell Lung Cancer (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS)
- Sphenopalatine Ganglion Block for Headache
- Spinal Cord and Dorsal Root Ganglion Stimulation
- Statin
- Stereotactic Radiosurgery and Stereotactic Body Radiotherapy
- Steroid-Eluting Sinus Stents and Implants
- Surgical Deactivation of Headache Trigger Sites
- Surgical Treatment for Gender Dysphoria
- Surgical Treatment of Gynecomastia
- Surgical Treatment of Snoring and Obstructive Sleep Apnea (OSA) Syndrome
- Surgical Treatment of Snoring and Obstructive Sleep Apnea Syndrome
- Testing Serum Vitamin D Levels
- Tezspire
- Total Ankle Replacement
- Total Artificial Hearts and Ventricular Assist Devices
- Transcatheter Aortic Valve Implantation for Aortic Stenosis
- Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies
- Transcranial Magnetic Stimulation (TMS) as a Treatment of Depression and Other Psychiatric/Neurologic Disorders
- Transesophageal Endoscopic Therapies for Gastroesophageal Reflux Disease
- Treatment of Hyperhidrosis
- Treatment of Tinnitus
- Tumor Treating Fields Therapy
- Ultrafiltration in Heart Failure
- Ultraviolet Light Therapy for Skin Conditions
- Vagus Nerve Stimulation
- Vagus Nerve Stimulation
- Video Electroencephalogram (EEG) Monitoring
- Virtual Colonoscopy / CT Colonography
- Weight Loss Agents
- Wireless Capsule Endoscopy for Gastrointestinal (GI) Disorders
- Wireless Capsule Endoscopy to Diagnose Disorders of the Small Bowel, Esophagus, and Colon
- Xolair
- Zolgensma
- Zolgensma Medical Drug Criteria

